More Teva moves to ease looming patent loss pain with Labrys buy

By Gareth Macdonald

- Last updated on GMT

More Teva moves to ease looming patent loss pain with Labrys buy

Related tags Clinical trial Teva

Teva Pharmaceutical Industries plans to buy Labrys Biologics for up to $825m to add a promising migraine treatment to its portfolio of pain drugs.

The deal – which will see Teva pay $200m upfront and up to $625m more on the achievement of certain milestones – is focused on the monoclonal antibody (mAb) LBR-101, which is currently in Phase II trials for chronic migraine​.

The drug was developed by Rinat Neurosciences. However, in 2006, it was bought​ by Pfizer along with a second mAb RN1219, since renamed PF-04360365, which is now in a Phase II trial​ for cerebral amyloid angiopathy after earlier studies in Alzheimer’s were unsuccessful​.

Teva said acquiring LBR-101 expands its pain portfolio which includes the blockbuster Copaxone – currently the subject of a complex patent battle​ – and a second migraine drug, Zecuity, gained in January​ though the takeover of NuPathe.

News of the planned Labrys deal comes just a day after Teva announced it will reorganise​ its executive team, appoint an overall chief of product quality and merge its generic business into a global unit under the leadership of Sigurdur Olafsson.

Related topics Markets & Regulations

Related news